Eric Carpentier, Ph.D. - Publications

Affiliations: 
2011 Université de Montréal, Montréal, Canada 

8 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Mancini AD, Bertrand G, Vivot K, Carpentier É, Tremblay C, Ghislain J, Bouvier M, Poitout V. β-Arrestin Recruitment and Biased Agonism at Free Fatty Acid Receptor 1. The Journal of Biological Chemistry. 290: 21131-40. PMID 26157145 DOI: 10.1074/Jbc.M115.644450  0.526
2014 Ceraudo E, Galanth C, Carpentier E, Banegas-Font I, Schonegge AM, Alvear-Perez R, Iturrioz X, Bouvier M, Llorens-Cortes C. Biased signaling favoring gi over β-arrestin promoted by an apelin fragment lacking the C-terminal phenylalanine. The Journal of Biological Chemistry. 289: 24599-610. PMID 25012663 DOI: 10.1074/Jbc.M113.541698  0.532
2014 Mancini A, Bertrand G, Vivot K, Carpentier E, Ghislain J, Bouvier M, Poitout V. Beta-Arrestin 2 Recruitment and Biased Agonism at the Free Fatty Acid Receptor GPR40 Canadian Journal of Diabetes. 38: S66. DOI: 10.1016/J.Jcjd.2014.07.187  0.487
2013 Mancini AD, Carpentier É, Bouvier M, Poitout V. TAK-875 is a Partial Agonist of the Free Fatty Acid Receptor GPR40 Canadian Journal of Diabetes. 37: S59. DOI: 10.1016/J.Jcjd.2013.08.176  0.52
2012 Carpentier E, Greenbaum LA, Rochdi D, Abrol R, Goddard WA, Bichet DG, Bouvier M. Identification and characterization of an activating F229V substitution in the V2 vasopressin receptor in an infant with NSIAD. Journal of the American Society of Nephrology : Jasn. 23: 1635-40. PMID 22956819 DOI: 10.1681/Asn.2012010077  0.673
2010 Rochdi MD, Vargas GA, Carpentier E, Oligny-Longpré G, Chen S, Kovoor A, Gitelman SE, Rosenthal SM, von Zastrow M, Bouvier M. Functional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments. Molecular Pharmacology. 77: 836-45. PMID 20159941 DOI: 10.1124/Mol.109.061804  0.575
2010 Bockenhauer D, Carpentier E, Rochdi D, van't Hoff W, Breton B, Bernier V, Bouvier M, Bichet DG. Vasopressin type 2 receptor V88M mutation: molecular basis of partial and complete nephrogenic diabetes insipidus. Nephron. Physiology. 114: p1-10. PMID 19816050 DOI: 10.1159/000245059  0.478
2001 Carpentier E, Lebesgue D, Kamen AA, Hogue M, Bouvier M, Durocher Y. Increased production of active human beta(2)-adrenergic/G(alphas) fusion receptor in Sf-9 cells using nutrient limiting conditions. Protein Expression and Purification. 23: 66-74. PMID 11570847 DOI: 10.1006/Prep.2001.1476  0.525
Show low-probability matches.